ECONOMIC EVALUATION OF BEVACIZUMAB VERSUS RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CHINA

被引：0
|
作者：
Li, H. [1 ]
Li, X. [2 ]
Xie, F. [3 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
[2] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
[3] McMaster Univ, Hamilton, ON, Canada
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.385
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS8
引用
收藏
页码：A782 / A782
页数：1
相关论文
共 50 条
  • [1] Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
    Chakravarthy, Usha
    Harding, Simon P.
    Rogers, Chris A.
    Downes, Susan M.
    Lotery, Andrew J.
    Wordsworth, Sarah
    Reeves, Barnaby C.
    [J]. OPHTHALMOLOGY, 2012, 119 (07)
  • [2] Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration
    Abouammoh, Marwan
    Sharma, Sanjay
    [J]. CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 152 - 158
  • [3] Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
    Moja, Lorenzo
    Lucenteforte, Ersilia
    Kwag, Koren H.
    Bertele, Vittorio
    Campomori, Annalisa
    Chakravarthy, Usha
    D'Amico, Roberto
    Dickersin, Kay
    Kodjikian, Laurent
    Lindsley, Kristina
    Loke, Yoon
    Maguire, Maureen
    Martin, Daniel F.
    Mugelli, Alessandro
    Muehlbauer, Bernd
    Puentmann, Isabel
    Reeves, Barnaby
    Rogers, Chris
    Schmucker, Christine
    Subramanian, Manju L.
    Virgili, Gianni
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (09):
  • [4] Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
    Martin, Daniel F.
    Maguire, Maureen G.
    Fine, Stuart L.
    Ying, Gui-shuang
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Redford, Maryann
    Ferris, Frederick L., III
    [J]. OPHTHALMOLOGY, 2012, 119 (07) : 1388 - 1398
  • [5] Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis
    Wang, Wen-Jie
    Chen, Jian
    Zhang, Xiao-Ling
    Yao, Min
    Liu, Xiao-Yong
    Zhou, Qing
    Qu, Yi-Xin
    [J]. INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2015, 8 (01) : 138 - 147
  • [6] Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration
    Heroman, J. Wesley
    Kaplan, Henry J.
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 491 - 497
  • [7] Bevacizumab for Neovascular Age-related Macular Degeneration in China
    Li, Xiaoxin
    Hu, Yonghua
    Sun, Xiaodong
    Zhang, Junjun
    Zhang, Maonian
    [J]. OPHTHALMOLOGY, 2012, 119 (10) : 2087 - 2093
  • [8] Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    Brown, David M.
    Kaiser, Peter K.
    Michels, Mark
    Soubrane, Gisele
    Heier, Jeffrey S.
    Kim, Robert Y.
    Sy, Judy P.
    Schneider, Susan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1432 - 1444
  • [9] Ranibizumab for neovascular age-related macular degeneration
    Rosenfeld, Philip J.
    Brown, David M.
    Heier, Jeffrey S.
    Boyer, David S.
    Kaiser, Peter K.
    Chung, Carol Y.
    Kim, Robert Y.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1419 - 1431
  • [10] Ranibizumab Versus Bevacizumab for Neovascular Age-Related Macular Degeneration With an Incomplete Posterior Vitreous Detachment
    Rush, Ryan B.
    Rush, Sloan W.
    [J]. ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2016, 5 (03): : 171 - 175
12345